Fig. 4: Elevated MZT2B expression is observed in locally-treated human NSCLC tissues and various NSCLC cell types. | Cell Death & Disease

Fig. 4: Elevated MZT2B expression is observed in locally-treated human NSCLC tissues and various NSCLC cell types.

From: MZT2B promotes malignant phenotypes in NSCLC cells by enhancing mitochondrial function and COX5B expression

Fig. 4

Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was performed to assess MZT2B mRNA transcript levels in paired NSCLC tumor specimens (T) and adjacent non-malignant lung tissues (N) (n = 20, A). Representative western blotting analyses were conducted on MZT2B protein lysates from four individual patient pairs to investigate MZT2B protein expression in NSCLC tumor specimens relative to matched normal tissues (B). Quantitative densitometric analysis of Western blotting was performed across the entire patient cohort (n = 20) to confirm MZT2B protein abundance in NSCLC tumor tissues compared to adjacent non-malignant controls (C). qRT-PCR analysis was utilized to measure MZT2B mRNA transcript levels in various primary human NSCLC cells (pNSCLC1, pNSCLC2, pNSCLC3) and the A549 cell line, in comparison to normal primary human lung epithelial cells (pEpi1, pEpi2) (D). Western blot analysis was subsequently carried out to examine MZT2B protein expression in the NSCLC cells relative to normal lung epithelial controls (E). Error bars represent the mean ± standard deviation (SD), with statistical significance *P < 0.05 when comparing to “N” tissues or “pEpi1” cells.

Back to article page